Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 1000 participants.

Also called NCT01120301

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,000 participants (planned count) (from the registry)
Sponsor
PhotoThera, Inc (from the registry)
Registry
  • NCT NCT01120301
Other papers using this trial's data
  • Transcranial laser therapy in acute stroke treatment: results of neurothera effectiveness and safety trial 3, a phase III clinical end point device trial Stroke, 2014-11 DOI, PubMed 25293665

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Countries
United States, Austria, Canada, Finland, France, Germany, Peru, Spain, Sweden, Switzerland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01120301. Randomized; quadruple masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2012-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
Acronym
NEST-3
Condition
Acute Ischemic Stroke
Intervention (Device)
NeuroThera® Laser System
Lead sponsor
PhotoThera, Inc (class: industry)

Record details

Record id
cardio:ct-nct01120301
Content hash
fe408b61b8877c4ad249d9ce4df0c9ea97a46f1bf55ffd68cfd7dc17f92fb27e